What Is Fengycin? Definition and What Research Reports

Definition

Fengycin is the name given to a family of cyclic lipopeptides produced by certain strains of the soil bacterium genus Bacillus, most often Bacillus subtilis and Bacillus amyloliquefaciens. Structurally, a fengycin molecule combines a chain of ten amino acids — part of which is closed into a ring through a lactone bond — with a fatty acid tail of variable length attached at one end. Because it carries both a water-attracting peptide portion and a fat-attracting lipid portion, fengycin behaves as a biosurfactant, and this amphiphilic character is the usual starting point for how the molecule is described in the microbiology literature. The term is definitional rather than clinical: fengycin is a naturally occurring bacterial metabolite studied mainly in agricultural, food-science and fermentation contexts, not an approved drug product.

What Class of Molecule Is Fengycin?

Fengycin belongs to the non-ribosomal peptides. Unlike the peptides most readers encounter in pharmacology — which are translated from messenger RNA by ribosomes — fengycin is assembled by large multi-enzyme assembly lines called non-ribosomal peptide synthetases (NRPS). These enzymes select and link amino acids in a fixed order without a genetic template being read at the ribosome, which is why fengycin can incorporate unusual residues, including D-configuration amino acids and ornithine, that are not part of the standard twenty used in ribosomal protein synthesis.

Within the lipopeptide world, fengycin is conventionally grouped alongside two other Bacillus-derived families, surfactin and iturin. The three families differ in ring size, amino acid composition and lipid tail chemistry. Fengycin itself is usually reported as a mixture of closely related congeners rather than a single compound; the variants differ in the length and branching of the fatty acid chain and in one amino acid position, giving rise to the labels fengycin A and fengycin B in much of the published work.

Where Fengycin Comes From

Fengycin is a secondary metabolite — a compound a bacterium makes beyond what it needs for basic growth. Production is strain-dependent and strongly influenced by culture conditions, which is why a large share of the fengycin literature is devoted to fermentation rather than to the molecule's biology. A 2024 review in Microbial Cell Factories surveyed strategies for improving fengycin production, covering strain selection, genetic engineering of the biosynthetic pathway, and optimisation of culture media and fermentation processes (PMID 38773450). That body of work exists because wild-type yields are generally low and because fengycin is co-produced with other lipopeptides, complicating purification.

Nutritional and genetic control of output

Researchers have looked at both what a strain is fed and how its regulatory machinery behaves. A 2016 study in the Journal of Applied Microbiology examined the effect of fructose on fengycin biosynthesis in Bacillus amyloliquefaciens fmb-60 and reported that the carbon source promoted fengycin formation (PMID 27611603). On the genetic side, a 2018 paper in Archives of Microbiology reported that polynucleotide phosphorylase, an RNA-processing enzyme, was involved in the control of fengycin production in Bacillus subtilis (PMID 29423562). More recently, a 2024 report in the Journal of Natural Products described an engineered microbial consortium that supplied precursors for fengycin production by Bacillus subtilis (PMID 38204395), an approach that divides the metabolic workload between organisms instead of loading it onto a single producer strain.

How the Term Is Used in Peptide Research

In peptide science, "fengycin" is used in three fairly distinct ways. First, as a structural label: a specific lipopeptide family with a defined ring architecture, cited when authors classify natural products or compare NRPS assembly lines. Second, as a model system for studying how non-ribosomal peptides are made and regulated — the biosynthetic gene cluster and its control points are a recurring subject, as in the polynucleotide phosphorylase work (PMID 29423562). Third, as a bioprocess target, where the interest lies in raising titres for downstream applications rather than in the molecule's mechanism, which is the framing of the 2024 production review (PMID 38773450).

It is worth separating fengycin from the research peptides most often discussed in human physiology. Fengycin is not a signalling peptide, a growth factor fragment or a hormone analogue; the literature treats it as a microbial antifungal metabolite and surfactant. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, treatment or the interpretation of research findings.

What the Published Literature Reports

Activity against fungi and mycotoxins

The best-represented theme is antifungal and anti-mycotoxin activity in laboratory and food-science settings. A 2019 study in Toxins reported that fengycin produced by Bacillus amyloliquefaciens FZB42 inhibited the growth of the cereal pathogen Fusarium graminearum and interfered with mycotoxin biosynthesis by that fungus (PMID 31137632). A separate 2022 paper in Open Life Sciences investigated the mechanism by which fengycin inhibited production of patulin, a mycotoxin associated with spoiled fruit (PMID 35528279). Both reports sit in the biocontrol and food-safety literature and describe fungal systems rather than animals or people.

Cell-culture work

One line of enquiry has looked beyond fungi. A 2016 study in Neoplasma examined fengycin derived from Bacillus subtilis fmbJ and reported an anti-tumour role against the human colon cancer cell line HT29 in culture (PMID 26774143). This was cell-line work; findings in a dish do not establish what happens in an intact organism, and the verified literature summarised here contains no human trials of fengycin.

What the literature does not establish

• No clinical trial of fengycin in humans appears among the papers cited on this page.
• No approved medicine containing fengycin is identified in this literature; the molecule is discussed as a natural product and research material.
• Fengycin preparations described in research are often mixtures of congeners, so results reported for one preparation may not transfer to another.

Adverse Events: What Studies Report

The verified papers summarised here are microbiological, fermentation-focused or cell-culture studies, and none of them reported human adverse-event data for fengycin. The 2016 Neoplasma report described effects on a cultured human colon cancer cell line (PMID 26774143), while the antifungal work characterised inhibition of fungal growth and toxin formation (PMID 31137632). Because no dosing study in people is present in this set, no safety profile, tolerability range or exposure limit can be summarised from it.

Common Points of Confusion

• Fengycin vs. plipastatin. The two names refer to very closely related lipopeptide structures and are often discussed together in the literature.
• Fengycin vs. surfactin and iturin. All three are Bacillus lipopeptide families, but they differ in ring size, amino acid composition and lipid chemistry, and findings reported for one family do not automatically apply to another.
• Fengycin vs. ribosomal peptides. Fengycin is assembled by NRPS enzymes, so it is not encoded as a translated gene product in the way that insulin or GLP-1 analogues are.
• A single compound vs. a mixture. "Fengycin" in a methods section frequently denotes a family of homologues rather than one purified molecule.

References

• Strategies for improving fengycin production: a review (Microbial Cell Factories, 2024)
• Fengycin Produced by Bacillus amyloliquefaciens FZB42 Inhibits Fusarium graminearum Growth and Mycotoxins Biosynthesis (Toxins, 2019)
• Anti-tumor role of Bacillus subtilis fmbJ-derived fengycin on human colon cancer HT29 cell line (Neoplasma, 2016)
• Polynucleotide phosphorylase is involved in the control of lipopeptide fengycin production in Bacillus subtilis (Archives of Microbiology, 2018)
• Effect of fructose on promoting fengycin biosynthesis in Bacillus amyloliquefaciens fmb-60 (Journal of Applied Microbiology, 2016)
• An Engineered Microbial Consortium Provides Precursors for Fengycin Production by Bacillus subtilis (Journal of Natural Products, 2024)
• Study on the mechanism of inhibiting patulin production by fengycin (Open Life Sciences, 2022)